News Releases
2008 
15/05/2008PROJET D’EXTENSION DU SITE DE MERCK SERONO À CORSIER-SUR-VEVEY : CONCLUSIONS DE LA NOTICE D’IMPACT SUR L’ENVIRONNEMENTGenève, Suisse German French
05/05/2008UNIQUE THREE-YEAR DATA DEMONSTRATING LONG-TERM EFFICACY AND SAFETY OF RAPTIVA® IN THE TREATMENT OF PSORIASIS PUBLISHED IN THE BRITISH JOURNAL OF DERMATOLOGY Geneva, Switzerland German French English
30/04/2008MERCK SERONO ANNOUNCES INITIATION OF PHASE II CLINICAL TRIAL OF ATACICEPT IN RELAPSING MULTIPLE SCLEROSISGeneva, Switzerland French German English
16/04/2008MERCK ANNOUNCES PLANNED INVESTMENT OF $50 MILLION IN RESEARCH CENTER IN THE US Geneva, Switzerland French German English
19/03/2008MERCK SERONO LAUNCHES CYANOKIT® IN JAPANGeneva, Switzerland French German English
 
2007 
20/12/2007MERCK SERONO AND FLAMEL TO COLLABORATE ON AN EXTENDED RELEASE FORMULATION FOR THERAPEUTIC PROTEINSGeneva, Switzerland German French English
19/12/2007MERCK KGAA IDERA PHARMACEUTICALS TO COLLABORATE ON DEVELOPMENT OF TLR9 AGONISTS FOR TREATMENT OF CANCERGeneva, Switzerland German English
18/12/2007MERCK SERONO LAUNCHES NEW WEBSITEGeneva, Switzerland French German English
13/12/2007MERCK SERONO ANNOUNCES SUPPORT OF THE MICHAEL J. FOX FOUNDATION FOR PARKINSON’S RESEARCHGeneva, Switzerland French German English
13/12/2007MERCK SERONO ANNOUNCES INITIATION OF PHASE II/III CLINICAL TRIAL OF ATACICEPT IN LUPUS NEPHRITISGeneva, Switzerland French German English
29/11/2007NEW DATA HIGHLIGHT THAT TREATMENT WITH ERBITUX ALLOWS MORE RESECTIONS OF PRETREATED PATIENTS WITH METASTATIC COLORECTAL CANCERGeneva, Switzerland English
28/11/2007MERCK SERONO INITIATES THE MOTION STUDY, A NEW PHASE III CLINICAL TRIAL OF SAFINAMIDE IN PARKINSON’S DISEASEGeneva, Switzerland French German English
14/11/2007STUDY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE SHOWS ERBITUX IMPROVES SURVIVAL IN METASTATIC COLORECTAL CANCERGeneva, Switzerland English
11/11/2007MERCK SERONO’S CYANOKIT® APPROVED IN THE EUROPEAN UNIONGeneva, Switzerland French German English
08/11/2007MERCK SERONO SUBMITS EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR SAPROPTERIN AS A TREATMENT FOR HYPERPHENYLALANINEMIAGeneva, Switzerland French German English
08/11/2007FDA APPROVAL OF EASYPOD®: NEW ELECTRONIC GROWTH HORMONE INJECTION DEVICEGeneva, Switzerland French German English
31/10/2007MERCK SERONO AND EPFL ANNOUNCE RESEARCH PARTNERSHIP IN NEUROSCIENCE, ONCOLOGY AND DRUG DELIVERYGeneva, Switzerland French German English
17/10/2007MERCK SERONO ANNOUNCES JOINT AGREEMENT WITH IMCLONE AND BRISTOL-MYERS SQUIBB FOR ERBITUX IN JAPANGeneva, Switzerland English
11/10/2007TWO-YEAR PHASE IIIB DATA SHOW THAT THE NEW FORMULATION OF REBIF® OFFERS A NEAR THREE-FOLD IMPROVEMENT IN INJECTION TOLERABILITY AND REDUCED IMMUNOGENICITYGeneva, Switzerland French German English
26/09/2007DATA REINFORCE THE VALUE OF UFT® AS AN IMPORTANT TREATMENT OPTION FOR PATIENTS WITH METASTATIC COLORECTAL CANCERGeneva, Switzerland English
25/09/2007SAFETY AND EFFICACY OF ERBITUX® CONFIRMED FOR COMBINATION TRIALSGeneva, Switzerland English
24/09/2007 MERCK SERONO’S CYANOKIT® RECOMMENDED FOR EUROPEAN APPROVALGeneva, Switzerland German English
11/09/2007ERBITUX PHASE III STUDY – FLEX INCREASES OVERALL SURVIVAL IN FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCERGeneva, Switzerland English
05/09/2007STIMUVAX® THERAPEUTIC CANCER VACCINE – PHASE II DATA HIGHLIGHT THREE-YEAR SURVIVAL RESULTS FOR LUNG CANCER PATIENTSGeneva, Switzerland English
03/09/2007MERCK SERONO APPLIES TO EXTEND USE OF ERBITUX® FOR 1ST-LINE COLORECTAL CANCERGeneva, Switzerland English
30/08/2007NEW FORMULATION OF MULTIPLE SCLEROSIS TREATMENT REBIF® APPROVED IN EUROPEAN UNIONGeneva, Switzerland French German English
29/08/2007MERCK SERONO TO RECONSIDER DEVELOPMENT OF MATUZUMAB IN METASTATIC COLORECTAL CANCER PATIENTSGeneva, Switzerland English
22/08/2007MERCK SERONO ANNOUNCES 18-MONTH SAFETY AND EFFICACY DATAOF PHASE III TRIAL OF SAFINAMIDE IN PARKINSON’S DISEASEGeneva, Switzerland English
06/07/2007SQUEEZE OUT OF MERCK SERONO SHARES SUCCESSFULLY COMPLETEDGeneva, Switzerland French German English
29/06/2007MERCK SERONO’S FERTILITY TREATMENT PERGOVERIS™ APPROVED IN EUROPEAN UNIONGeneva, Switzerland French German English
28/06/2007EUROPEAN UNION CHMP RECOMMENDS APPROVAL OF NEW FORMULATION OF MULTIPLE SCLEROSIS TREATMENT REBIF® (INTERFERON BETA-1A)Geneva, Switzerland French German English
19/06/2007MERCK SERONO AND AMBRX TO COLLABORATE ON DEVELOPMENT OF NEXT GENERATION GROWTH HORMONE PRODUCTSGeneva, Switzerland French German English
18/06/2007EASYPOD™ PATIENT FRIENDLY INJECTION DEVICE RECOGNIZED BY TECHNOLOGY AWARDGeneva, Switzerland French German English
15/06/2007INAUGURATION OF MERCK SERONO’S NEW GLOBAL HEAD OFFICE IN GENEVAGeneva, Switzerland French German English
08/06/2007PROMISING DATA ON COGNITIVE EFFECTS OF SAFINAMIDEIN EARLY PARKINSON’S DISEASEGeneva, Switzerland French German English
04/06/2007MERCK SERONO S.A. TO TERMINATE REGISTRATION AND DUTY TO FILE REPORTS UNDER THE U.S. SECURITIES EXCHANGE ACTGeneva, Switzerland French German English
04/06/2007CLOSING OF THE EXISTING SHARE-REPURCHASE PROGRAM OF UP TO CHF 750 MILLION BY JUNE 1, 2007Geneva, Switzerland French English
16/05/2007INAUGURATION DE L’ESPACE DE VIE ENFANTINE CRESCENDOGenéve, Suisse French
02/05/2007PHASE III DATA ON SAFINAMIDE IN PARKINSON'S DISEASE PRESENTED AT AMERICAN ACADEMY OF NEUROLOGY 59TH ANNUAL MEETINGGeneva, Siwtzerland French English
27/04/2007MERCK SERONO ANNOUNCES PRESENTATION OF PHASE III CLINICAL DATA ON SAFINAMIDE IN PARKINSON’S DISEASE AT THE AMERICAN ACADEMY OF NEUROLOGY 59TH ANNUAL MEETINGGeneva, Switzerland French German
05/04/2007MERCK SERONO S.A. TO VOLUNTARILY DELIST AND DEREGISTER ITS BEARER SHARES AND AMERICAN DEPOSITARY SHARES (EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS)Geneva, Switerland French German English
21/03/2007MERCK SERONO CONFIRMS PREVIOUSLY ANNOUNCED 2006 FIGURESGeneva, Switzerland French German English
21/03/2007MERCK INITIATES SQUEEZE OUT PROCEDURE FOR SHARES OF MERCK SERONO S.A.Geneva, Switzerland French German English
01/03/2007MERCK KGAA ANNOUNCES SERONO PRELIMINARY FIGURES FOR 2006Geneva, Switzerland French German English
28/02/2007MERCK KGAA HOLDS NEARLY ALL VOTING RIGHTS IN MERCK SERONO S.A.Geneva, Switzerland English
30/01/2007MERCK SERONO LAUNCHES EASYPOD®, FIRST ELECTRONIC GROWTH HORMONE INJECTION DEVICEGeneva, Switzerland French German English
24/01/2007MERCK SERONO HAS INITIATED THE ONWARD STUDY TO EVALUATE ORAL CLADRIBINE AS ADD-ON TREATMENT FOR MULTIPLE SCLEROSISGeneva, Switzerland French German English
16/01/2007MERCK SERONO COMPLETES PATIENT ENROLLMENT IN CLARITY PHASE III PIVOTAL CLINICAL TRIAL OF ORAL CLADRIBINEGeneva, Switzerland French German English
16/01/2007MERCK SERONO ANNOUNCES POSITIVE RESULTS FROM PHASE III DIET STUDY OF PHENOPTIN FOR PHENYLKETONURIAGeneva, Switzerland French German English
09/01/2007MERCK KGAA ANNOUNCES PUBLIC TENDER OFFER FOR MERCK SERONO SHARESDarmstadt, Germany English
08/01/2007MERCK SERONO IS LAUNCHEDGeneva, Switzerland French German English
05/01/2007MERCK KGAA ACQUIRES MARJORITY SHAREHOLDING IN SERONO S.A.Geneva, Switzerland English
 
2006 
20/12/2006ZYMOGENETICS AND SERONO BEGIN PHASE 2 CLINICAL TRIAL WITH ATACICEPT IN RHEUMATOID ARTHRITISGeneva, Switzerland French German English
18/12/2006MERCK KGAA: EUROPEAN ANTITRUST AUTHORITIES CLEAR ACQUISITION OF SERONOGeneva, Switzerland English
12/12/2006SERONO ANNOUNCES INITIATION OF THE REFLEX TRIAL TO EVALUATE NEW FORMULATION OF REBIF® IN PATIENTS AT RISK OF DEVELOPING MULTIPLE SCLEROSISGeneva, Switzerland French German English
13/11/2006ZYMOGENETICS AND SERONO REPORT DETAILED POSITIVE RESULTS FROM ATACICEPT PHASE 1B CLINICAL TRIAL IN PATIENTS WITH LUPUSSeattle, USA and Geneva, Switzerland French German English
31/10/200624-WEEK CLEAR STUDY RESULTS CONFIRM SUSTAINED EFFICACY AND SAFETY OF RAPTIVA® IN MODERATE-TO-SEVERE PSORIASIS PATIENTS WITH CO-MORBIDITIESGeneva, Switzerland French German English
26/10/2006SERONO AND NEWRON ANNOUNCE GLOBAL DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR SAFINAMIDEGeneva, Switzerland and Milan, Italy French German English
26/10/2006FINAL DATA FROM TWO PHASE II TRIALS INDICATE ACTIVITY OF ADECATUMUMAB (MT201) IN BREAST AND PROSTATE CANCERCarlsbad, CA and Geneva, Switzerland French German English
19/10/2006SERONO DELIVERS STRONG ADJUSTED* NET INCOME OF $183.5M IN THIRD QUARTER 2006Geneva, Switzerland French German English
19/10/2006FINANCIAL TABLESGeneva, Switzerland English
28/09/2006ONE-YEAR DATA FROM PHASE III TRIAL SHOW THAT NEW FORMULATION OF REBIF® OFFERS SUBSTANTIAL IMPROVEMENT IN TOLERABILITY AND IMMUNOGENICITY PROFILESMadrid, Spain French English
25/09/2006PUBLICATION OF INTERESTS (Art. 21 LBVM [SWISS STOCK MARKET LAW])Geneva, Switzerland French German English
21/09/2006SERONO'S ORAL CLADRIBINE FOR THE TREATMENT OF MULTIPLE SCLEROSIS AWARDED FAST TRACK STATUS BY FDAGeneva, Switzerland French German English
21/09/2006MERCK KGAA TO ACQUIRE SERONOGeneva, Switzerland English
18/09/2006SERONO AND SYNTONIX TO PURSUE THE DEVELOPMENT OF A LONG-ACTING, INHALEABLE FSH THERAPY TO TREAT INFERTILITYGeneva, Switzerland and Waltham, Mass French German English
12/09/2006BIOMARIN AND SERONO ANNOUNCE DATA ON PHENOPTIN IN PKU TO BE PRESENTED AT THE 56TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HUMAN GENETICNovato, California and Geneva, Switzerland English
26/07/2006SERONO DELIVERS SECOND QUARTER EPS OF $12.92, UP 25.2% ON ADJUSTED BASISGeneva, switzerland French German English
26/07/2006FINANCIAL TABLESGeneva, Switzerland English
24/07/2006SERONO INITIATES FIRST LARGE SCALE EUROPEAN PHARMACO-EPIDEMIOLOGICAL STUDY IN PSORIASIS TO FURTHER DOCUMENT THE DEMONSTRATED LONG-TERM SAFETY PROFILE OF RAPTIVA®Geneva, Switzerland French German English
10/07/2006EUROPEAN COMMISSION APPROVES REVISION OF THERAPEUTIC INDICATION FOR REBIF®Geneva, Switzerland French German English
26/06/2006ZYMOGENETICS AND SERONO PRESENT POSITIVE RESULTS OF TACI-IG PHASE 1B TRIAL IN RHEUMATOID ARTHRITIS AT EULAR MEETINGSeattle, USA andGeneva, Switzerland French German English
22/06/2006COMPELLING EVIDENCE OF RAPTIVA® 12-WEEK CLEAR TRIAL DATA IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS PUBLISHED IN BRITISH JOURNAL OF DERMATOLOGYGeneva, Switzerland French German English
09/05/2006SERONO ANNOUNCES NEW APPOINTMENTS TO ITS EXECUTIVE MANAGEMENT BOARDGeneva, Switzerland French German English
25/04/2006SERONO SHAREHOLDERS APPROVE RESOLUTIONS AT ANNUAL GENERAL MEETINGGeneva, Switzerland French German English
20/04/2006SERONO DELIVERS STRONG FIRST QUARTER 2006 WITH REVENUE GROWTH OF 16.4% IN LOCAL CURRENCIESGeneva, Switzerland French German English
20/04/2006FINANCIAL TABLESGeneva, Switzerland English
10/04/2006SERONO ANNOUNCES TERMINATION OF DISCUSSIONS CONCERNING A SALE OF THE COMPANYGeneva, Switzerland French German English
04/04/2006SERONO SUBMITS NEW FORMULATION OF REBIF® FOR APPROVAL IN THE UNITED STATES AND IN EUROPEGeneva, Switzerland and Rockland, MA French German English
31/03/2006SERONO’S BOARD OF DIRECTORS TO PROPOSE AN INCREASE IN AUTHORIZED SHARE CAPITAL TO THE FORTHCOMING ANNUAL SHAREHOLDERS’ MEETING TO PROVIDE THE COMPANY WITH FINANCING CAPACITYGeneva, Switzerland French German English
15/03/2006BIOMARIN AND SERONO ANNOUNCE POSITIVE RESULTS FROM PHASE 3 CLINICAL STUDY OF PHENOPTIN FOR PKUNovato, CA and Geneva, Switzerland French German English
06/02/2006SERONO'S 2005 ADJUSTED* EPS INCREASED BY 34.6% Geneva, Switzerland French German English
06/02/2006FINANCIAL TABLESGeneva, Switzerland English
24/01/2006SERONO’S GONAL-F® APPROVED IN JAPAN FOR THE TREATMENT OF MALE HYPOGONADOTROPIC HYPOGONADISMGeneva, Switzerland French German English
09/01/2006SERONO COMPLETES SECOND PHASE III TRIAL OF ITS PROPRIETARYGeneva, Switzerland and Rockland, MA French German English
 

        © 2007-2008 Merck Serono International S.A.
        Last updated: 15/05/2008